StreetInsider.com News Articles

Nyxoah SA (NYXH) PT Lowered to $3 at Stifel post SLEEP Conference

Wed, 17 Jun 2026 07:08:40 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $3.00 (from $5.00) while maintaining a Hold rating.

The analyst commented, "Yesterday, we attended the SLEEP conference in Baltimore, MD and provide takeaways below.Inspire Medical: While more work needs to be done updating/educating facilities around prior reimbursement changes, we believe the worst is behind Inspire, and green shoots are starting to emerge. We take up our prior below Street 2Q26 revenue estimate and now reflect a -11% y/y decline (in-line with Street; 2026E moves modestly higher). We reiterate our stance that the stock is cheap, and although

Nyxoah SA (NYXH) PT Lowered to $3 at Stifel post SLEEP Conference

Wed, 17 Jun 2026 07:08:40 -0400

Stifel analyst Jonathan Block lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $3.00 (from $5.00) while maintaining a Hold rating.

Form 6-K Nyxoah SA For: Jun 11

Thu, 11 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26636633.html

Form 6-K Nyxoah SA For: Jun 11

Thu, 11 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26636633.html

Form 6-K Nyxoah SA For: Jun 11

Thu, 11 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260611/26636633.html

Form SCHEDULE 13D/A Nyxoah SA Filed by: Cochlear Ltd

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635894.html

Form SCHEDULE 13D/A Nyxoah SA Filed by: Cochlear Ltd

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635894.html

Form SCHEDULE 13D/A Nyxoah SA Filed by: Cochlear Ltd

Thu, 11 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260611/26635894.html

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

Nyxoah SA (Euronext Brussels/NASDAQ: NYXH) completed a $95 million equity financing and expects to receive a $15 million second tranche from its European Investment Bank loan by the end of June 2026, according to a press release statement.

The medical technology company develops treatments for obstructive sleep apnea and plans to use the $110 million in total capital to accelerate commercialization of its Genio system in the United States. The company currently has 40 sales representatives in place under U.S.-based commercial leadership.

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

Nyxoah raises $110 million to fund Genio sleep apnea device launch in US

Wed, 10 Jun 2026 16:30:24 -0400

"This is a defining moment for Nyxoah," said Olivier Taelman, Chief Executive Officer. "Building on the strong momentum of our

$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch

Wed, 10 Jun 2026 16:30:00 -0400